Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ESTRAMUSTINE PHOSPHATE SODIUM
- Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
- Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer
- Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
- Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
- Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
- Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
- Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
- S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
- Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer
- Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer
- Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
- Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer
- Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
- Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
- Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
- Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
- Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
- Combination Chemotherapy in Treating Patients With Advanced Cancer
- Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
- Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
- Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
- Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
- Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
- Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer
- Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
- Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
- Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer
- Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
- Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
- Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Clinical trials list
click for details